Targeted Suppression of the Transcription Factor Sox9
Targeted Suppression of the Transcription Factor Sox9
批准号:
7415283
负责人:
Manjeet Kumar Rao
金额:
$7.3万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-01 至 2008-07-31
关键词:
RNA interferenceSertoli cellscell differentiationgene induction /repressiongenetic promoter elementgenetically modified animalshomeobox geneslaboratory mousemicroRNAsnorthern blottingspolymerase chain reactionprotein structure functionribonuclease IIIspermatogenesistechnology /technique developmentterminal nick end labelingtestistranscription factorwestern blottings
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The transcription factor Sox9 is critical for the male gonadal development during embryogenesis. Sox9 expression also persists in some adult tissues, particularly in the testes, but its role after birth is not known, as conventional Sox9 knockout (KO) mice die during embryogenesis. In this application, I propose to determine Sox9's role in the postnatal and adult testes. I propose to accomplish this task by using a newly developed tissue specific RNA interference (RNAi) approach with a tool that I recently identified - a highly active promoter selectively expressed in Sertoli cells, the site of Sox9 expression in the testes. We have shown in our recent studies that only 0.6-kb 5'-flanking sequences from the proximal promoter of the RhoxS homeobox gene(RhoxS Pp) is sufficient to drive strong expression specifically in postnatal and adult Sertoli cells in a developmentally regulated manner in vivo. I propose to use RhoxS Pp to generate transgenic mice that express short hairpin (sh) RNAs specific for Sox9 in vivo. In addition to this study providing the first information on the role of Sox9 in the testes after birth, it will be a proof of principle for my newly developed in vivo RNAi approach that I used to knock down Wilms' tumor 1 gene (WT1) in a tissue-specific manner. This RNAi approach will be a technical advance, as to date no laboratory has reported the development of a generally applicable method for stable tissue-specific RNAi in vivo. My approach stems from the means by which naturally occurring short RNAs - micro RNAs (miRNAs) - are generated from Pol II transcripts. In my approach, a shRNA molecule targeting Sox9 will be processed from a RhoxS Pp-driven precursor transcript by Drosha, a ubiquitously expressed RNase-lll enzyme that processes out naturally occurring miRNAs. Because the Sox9 shRNA transcript will be specifically expressed from the RhoxS Pp, I predict it will suppress Sox9 expression specifically in Sertoli cells within the testes. I hypothesize that Sox9 functions in Sertoli cells to direct specific events during spermatogenesis. There are at least two lines of evidence that support my hypothesis : first, Sox9 is highly expressed in the adult Sertoli cells in a stage-specific manner suggesting that it might have a pivotal role in germ cell differentiation. Second, I recently showed that WT1, which is known to be highly expressed in adult Sertoli cells and plays a crucial role in gonadal development during embryogenesis like Sox9, is also important for maintenance of spermatogenesis. Therefore, I propose that Sox9 plays an important role in spermatogenesis. The specific aim of this application is: (1) to elucidate the function of transcription factor Sox9 in adult Sertoli cells by using tissue-specific RNAi. The elucidation of Sox9 function in postnatal testes may lead to better understanding of the pathophysiology of gonadal dysgenesis and sex-reversal commonly found in human patients with mutated Sox9. In addition, revelation of Sox9 function in reproduction may lead to treatments for infertility.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel approach of targeting AT-rich S/MAR regions for treating therapy resistant breast cancers
-
批准号:10744563
-
项目类别:
-
资助金额:$48.42万
-
财政年份:2023
-
负责人:Manjeet Kumar Rao
-
依托单位:
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers
-
批准号:9897345
-
项目类别:
-
资助金额:$42.93万
-
财政年份:2019
-
负责人:Manjeet Kumar Rao
-
依托单位:
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers
-
批准号:10533268
-
项目类别:
-
资助金额:$39.01万
-
财政年份:2019
-
负责人:Manjeet Kumar Rao
-
依托单位:
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers
-
批准号:10304196
-
项目类别:
-
资助金额:$39.04万
-
财政年份:2019
-
负责人:Manjeet Kumar Rao
-
依托单位:
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers
-
批准号:10533572
-
项目类别:
-
资助金额:$4.17万
-
财政年份:2019
-
负责人:Manjeet Kumar Rao
-
依托单位:
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers
-
批准号:10737772
-
项目类别:
-
资助金额:$6.57万
-
财政年份:2019
-
负责人:Manjeet Kumar Rao
-
依托单位:
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC
-
批准号:9212787
-
项目类别:
-
资助金额:$34.59万
-
财政年份:2015
-
负责人:Manjeet Kumar Rao
-
依托单位:
Importance of Androgen regulated miRNAs in male fertility
-
批准号:8889281
-
项目类别:
-
资助金额:$7.29万
-
财政年份:2014
-
负责人:Manjeet Kumar Rao
-
依托单位:
Catenins: A role in spertmatogenesis and sperm maturation
-
批准号:7937735
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2009
-
负责人:Manjeet Kumar Rao
-
依托单位:
Targeted Suppression of the Transcription Factor Sox9 in the Testis by Tissue-Spe
-
批准号:7263848
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2006
-
负责人:Manjeet Kumar Rao
-
依托单位:
国内基金
海外基金
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位: